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sparse data structures. Separation often leads to failure in convergence of 
maximum likelihood models or unrealistic parameter estimates with wide 
confidence intervals. Therefore, the study objective is to compare the empirical 
performance of alternative methods for modeling sparse data in the context of 
small sample sizes: Firth-bias corrected logistic regression, exact logistic 
regression, penalized logistic regressions macro implemented in STATA, removal 
of the variable causing separation, and a Bayesian logistic model with a weakly 
informative prior (WIP). METHODS: HIPAA compliant diabetes patient records 
were used for determining factors associated with exposure to Medication 
Therapy Management (MTM) services at high frequency. Potential predictors of 
MTM visit frequency included age, gender, medication regimen complexities and 
presence of diabetes-related complications. This dataset had a small sample size 
(n=121) and exhibited separation problem; all patients in the high visit frequency 
group had diabetes with complexity. We compared the results of the Bayesian 
model with a WIP (coefficients are assigned a N(0,1.38) prior) to results of 
deleting the problematic variable, exact logistic regression and two different 
algorithms for penalized log likelihood functions (Firth’s Bias-Correction in SAS 
and a STATA-Macro based routine). RESULTS: The Bayesian model with WIP 
produced odds ratio estimates of high frequency group membership based on 
diabetes complexity within expected range of treatment effects and plausible 
confidence intervals OR=4.64 (CI:0.98, 24.58). Among other models, only Firth-
Bias model converged but parameter estimates and confidence intervals were 
unrealistically large OR=210.9 (CI:1.83, >999.99). Removal of the problematic 
variable (diabetes complexity) from the model prevented assessment of its effect 
on the probability of high visit frequency membership. CONCLUSIONS: Bayesian 
models with WIP represent a useful tool for modeling health outcomes sparse 
data with small sample size.  
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OBJECTIVES: To explore the impact of inferences from very samples on the 
outcome of management decisions. In many cases management has some prior 
belief about the states of nature. We explore the potential advantage of 
incorporating Bayesian inference to improve the confidence in managerial 
decisions based on small samples.. Traditionally, survey researchers reconcile 
differences between survey results and prior beliefs by citing the uncertainty 
reflected in the sampling error or looking for other explanatory factors (such as 
possible survey measurement error). The Bayesian approach integrates the 
different sources of information (i.e., prior belief and observed survey results) to 
arrive at the most probable estimate. In full realization, a Bayesian approach 
considers not just the probability that “truth” lies outside some range of values 
but seeks to estimate the probability of each of many possible hypotheses, given 
the data was that obtained. METHODS: Using responses to a choice-based 
conjoint exercise that was embedded in an online survey of approximately 700 
individuals, we created a series of samples of different sizes using different 
restrictions to reflect the ways in which both probability and convenience 
samples might be generated. We drew multiples of ten random samples of 25, 
50, 75, 100, 150, 225 and 450 from our “population” of 897 respondents, resulting 
in 70 individual samples. We estimated HB models for each sample (using 
Sawtooth Software’s CBC-HB program). RESULTS: Simulated choice 
probabilities–a key output of discrete choice models–stabilize across samples 
starting with n=75. For smaller samples, decision confidence can be increased 
using Bayesian inference and bootstrapping methods. CONCLUSIONS: 
Meaningful inferences—and hence decisions–can be made with smaller sample 
sizes by utilizing Bayesian inference and methods such as bootstrapping to 
better estimate the degree of uncertainty in the data.  
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OBJECTIVES: Health utilities (HUs) are required to conduct cost-utility analyses 
(CUAs). Often, health-related quality of life (HRQOL) data, instead of HUs, are 
collected in clinical trials. Increasingly, mapping algorithms have been 
developed to derive HUs from HRQOL data. However, the variance of the derived 
HUs based on mapping are observed to be smaller than those of the actual HUs. 
METHODS: Two reasons are proposed: (1) the presence of important 
unmeasured predictors leading to a high degree of unexplained variance of 
derived HUs, and (2) ignoring that the regression coefficients are random 
variables themselves. We derive three variance estimators of HUs to account for 
these reasons: (1) R2-adjusted estimator, (2) parametric estimator and (3) non-
parametric estimator. We tested these estimators using a simulated dataset and 
a real dataset involving EQ-5D and University of Washington Quality of Life 
questionnaire for patients with head and neck cancers. RESULTS: The R2 
adjusted estimator can be used in ordinary least square (OLS) based mapping 
algorithms and requires only the R2from the derivation study. The parametric 
estimator can be used in OLS based mapping algorithms and requires the mean 
square error (MSE) and the design matrix from the derivation study. The non-
parametric estimator can be used in any mapping algorithm and requires leave-
one-out cross-validation MSE from the derivation study. In the simulated 
dataset, all three estimators are within 1% of the variance of the actual HUs. In 
the real dataset, the unadjusted variance was 44% less than the actual variance, 
while all three estimators are within 10% of the actual variance. CONCLUSIONS: 
When conducting CUA based on mapping algorithms, the variance of derived 
HUs should be properly adjusted using one of the proposed methods so that the 
results of the CUA will have the appropriate degree of uncertainty.  
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OBJECTIVES: In survey questions where the variable of interest is quantitative, 
responses often involve selecting one of several mutually exclusive intervals in 
which the variable lies within (denoted interval data). This precludes one from 
using many of the popularly reported measures of center (mean, median, mode, 
etc.). To this end, a simple estimator is proposed to estimate the population 
mean, μ, when the data are intervaled and its properties are studied. METHODS: 
For estimation of μ given intervaled data, we propose the Weighted Interval 
Midpoint Estimator (WIME). Expressions for its expected value and variance are 
derived. These are then calculated for normal distributions and a χ2 distribution 
on 1 degree of freedom using various interval configurations. Bootstrapping 
methods are then proposed to obtain estimates of the sampling distribution of 
the WIME as well as the sample mean given the interval counts. RESULTS:  
In general, the WIME is a biased estimator of μ; this bias is the same for all 
sample sizes. Simple bounds for the bias can derived. Both the bias and variance 
of the estimator depend on the choice of intervals. In the case of the normal 
distribution, equal-length intervals produce estimates with seemingly no  
bias and variance slightly above that of the sample mean as opposed to a  
non-equal-length configuration, even if the intervals are not symmetric about  
μ. For the χ2 distribution on 1 degree of freedom, using equal-length intervals 
produces estimates with less bias and variance than when using non- 
equal-length intervals. CONCLUSIONS: While the WIME is a quick and  
easy method to estimate μ, its performance depends on the intervals chosen. 
Thus prudence must be taken when selecting them. In the event no prior 
information exists to guide the process, equal-length intervals seem to be a safe 
fallback.  
 
PRM201  
A CAUTION ABOUT USING SAMPLE MEANS TO ESTIMATE INCREMENTAL 
COSTS FOR EXPENDITURES THAT FOLLOW A TRADITIONAL GAMMA 
DISTRIBUTION WITH PARAMETERS FOR SCALE AND SHAPE  
Juneau P 
Truven Health Analytics, Boyds, MD, USA  
OBJECTIVES: 1) To examine the practice of calculating a sample mean cost for 
each of two or more cohorts, reporting the difference(s) as the incremental 
cost(s), and reconciling this practice against the common assumption that the 
underlying expenditures follow a two-parameter gamma distribution, and 2) To 
revisit the interpretation of incremental costs based on the difference in sample 
means as the properties of the assumed underlying gamma distribution vary. 
METHODS: Monte Carlo gamma distribution simulation in SAS version 9.3 
varying the shape and scale parameters for the simulations and displaying the 
results in graphical and tabular format. RESULTS: It is possible to create 
examples of simulated data sets where the sample means have values that can 
be in excess of the estimated 75th percentile. CONCLUSIONS: An analyst should 
be cautious in his or her reporting of incremental costs as the lay consumer of 
these quantities may interpret the difference in the means like they would for 
two or more somewhat symmetrical distributions where the mean can represent 
the center. However, this interpretation might be misleading depending on the 
magnitude of the shape and scale parameters that characterize an underlying 
distribution's behavior.  
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OBJECTIVES: When evaluating multiple drugs for equivalence (or non-
inferiority) within the context of a Bayesian MTC, most studies base their 
interpretation solely on the point estimates and respective credible intervals. 
The following novel methodology advances interpretation by: Incorporating a 
pre-specified minimal clinically important difference (MCID); presenting a direct 
probability of equivalence (or non-inferiority), and graphically depicting how the 
probability varies by MCID. METHODS: As an illustrative example, we applied 
MTC to compare 12-week HbA1c reduction with vildagliptin 50 mg bid vs. 
sitagliptin 100 mg qd as monotherapies in patients with type 2 diabetes. 
Equivalence was assessed with a predefined equivalence margin of MCID. A 
Bayesian approach has the advantage of being able to provide probability 
statements for equivalence, to make direct inferential statement that the 
treatment effect between the two comparisons is between the specified lower 
and upper MCID (HbA1c ±0.7). The posterior probability of equivalence is 
calculated based on the area under the curve between lower and upper MCID on 
distribution of the mean change in HbA1c between the two comparisons. 
Sensitivity analysis was conducted by varying MCID values. RESULTS: The 
results of the MTC showed no significance difference between the two 
interventions in the reduction of HbA1c at 12 weeks (Δ = 0.16; 95% CrI -0.20 to 
0.52). However, this evidence of “no significant difference” does not prove 
equivalence. Applying the new method, at 12 weeks follow-up, the probability 
